Sign in
TerminatedPhase 1

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

Key facts

Who runs it
Hoffmann-La Roche
Where
Denver and Nashville, United StatesSee the 2 sites
Trial code
Status
Terminated
Phase
Phase 1
People taking part
3 people enrolled
Started
15 Jun 2023
Ended
19 Mar 2024
Type of study
Interventional, 3 groups
Treatments tested
  • RO7515629
  • tocilizumab
Record updated
9 July 2024
Why it stopped
Sponsor decision (not related to safety, efficacy or quality).

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Unresectable and/or metastatic HLA-G-positive solid tumors, for which standard therapy does not exist, or has proven to be ineffective or intolerable
  • Confirmed HLA-G tumor expression
  • Radiologically measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
  • Life expectancy of at least 12 weeks
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate hematological, liver, renal and pulmonary function
  • Willingness to abide by protocol defined contraceptive requirements for the duration of the study

Who cannot take part

  • Active interstitial lung disease (ILD), pneumonitis or a history of ILD/pneumonitis requiring treatment with steroids, history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest Computed Tomography (CT) scan
  • History of pulmonary embolism within 3 months prior to study entry
  • Presence of active or uncontrolled infection or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 weeks prior to initiation of study treatment
  • Major surgery within 28 days prior to first study treatment
  • Last treatment with anti-cancer therapy or any investigational drug 28 days or less prior to the first study treatment
  • Last dose of immunostimulating or immunosuppressive therapy 28 days or less prior to the first study treatment
  • Regular dose of corticosteroids that exceeds prednisone 10 mg/day or equivalent within 28 days prior to first study treatment
  • Prior treatment with T cell engaging or adoptive cell therapy
  • Administration of a live, attenuated vaccine 28 days or less prior to first study treatment
  • Rapid disease progression including lesions that are a threat to vital organs or non-irradiated lesions 2cm or larger at critical sites where tumor swelling may pose a risk to critical anatomical structures
  • Participants with another invasive malignancy in the last 2 years unless protocol specified criteria are met
  • Uncontrolled hypertension
  • Participants with central cavitation or tumor(s) shown to be invading or abutting major blood vessels by imaging or the Investigator determines the tumor(s) is likely to invade major blood vessels and cause fatal bleeding
  • Significant cardiovascular disease
  • Known hepatitis B or C (actively replicating) based on protocol specified criteria
  • Known Human Immunodeficiency Virus (HIV) positivity
  • Active auto-immune disease that has required systemic therapy within the past 2 years unless protocol specified exceptions are met
  • Contraindication or known hypersensitivity to any of the components of RO7515629 or tocilizumab or dexamethasone
  • History or clinical evidence of Central Nervous System (CNS) metastases unless protocol specified criteria are met
  • Leptomeningeal metastases
  • Participants with pulmonary military metastatic pattern or pulmonary lymphangitic carcinomatosis
  • Presence of an indwelling line or drain

Where in United States

  • Sarah Cannon Research Institute at HealthONEDenver, United States
  • SCRI Oncology PartnersNashville, United States

About the trial

What the trial wants to find out

The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, immune response and preliminary anti-tumor activity of RO7515629 alone in participants with advanced or metastatic solid tumors expressing human leukocyte antigen G (HLA-G).

The 3 groups in the trial

  • Part I Single Participant Cohort RO7515629 Dose EscalationTreatment being tested

    Participants will receive a fixed dose of RO7515629 intravenously as a single agent on cycle 0 day -7 and 7 days later on cycle 1 day 1 followed by every three-week dosing frequency. Treatment may continue for up to 12 months maximum or until progression, loss of clinical benefit, intolerable toxicity, withdrawal from study treatment or death.

    Treatment: RO7515629 and tocilizumab

  • Part II Multiple Participant Cohort RO7515629 Dose EscalationTreatment being tested

    Participants will receive RO7515629 intravenously, as a single agent on cycle 0 day -7 and 7 days later on cycle 1 day 1 followed by every three-week dosing frequency. In case of toxicity, step up dosing (single or double) may be implemented. Treatment may continue for up to 12 months maximum or until progression, loss of clinical benefit, intolerable toxicity, withdrawal from study treatment or death.

    Treatment: RO7515629 and tocilizumab

  • Part III Multiple Participant Cohort RO7515629 Dose ExpansionTreatment being tested

    Participants with selected solid tumors will receive a selected dose of RO7515629 intravenously as a single agent based on the recommended dose sequence for expansion (RDE) and dosing regimen selected from Part I and Part II. Treatment may continue for up to 12 months maximum or until progression, loss of clinical benefit, intolerable toxicity, withdrawal from study treatment or death.

    Treatment: RO7515629 and tocilizumab

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open-Label, Multicenter, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7515629 in Participants With Unresectable and/or Metastatic HLA-G Positive Solid Tumors
Publications
Record updated
9 July 2024